Value of [18F]-FDG positron emission tomography in patients with recurrent glioblastoma receiving bevacizumab.
Maya Srikanth GrahamSimone KrebsTejus BaleKwaku DomfeStephanie M LobaughZhigang ZhangMark P DunphyThomas KaleyRobert J YoungPublished in: Neuro-oncology advances (2020)
FDG PET is a promising imaging tool to further stratify prognosis in recurrent GBM patients on antiangiogenic therapy.